Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Jul 30;9(7):3766-3769.
doi: 10.4103/jfmpc.jfmpc_497_20. eCollection 2020 Jul.

Epistaxis presenting as sentinel feature of metastatic renal cell carcinoma: A case report and review of literature

Satish K Ranjan  1 , Ankur Mittal  1 , Sunil Kumar  1 , Kim J Mammen  1 , Shiv C Navariya  1 , Deepak P Bhirud  1
Affiliations
Case Reports

Epistaxis presenting as sentinel feature of metastatic renal cell carcinoma: A case report and review of literature

Satish K Ranjan et al. J Family Med Prim Care. .

Abstract

About 30% of all newly diagnosed renal cell carcinoma (RCC) patients present with synchronous metastatic disease. Usual organs of involvement are lung (75%), soft tissues (36%), bone (20%), liver (18%), cutaneous sites (8%), and central nervous system (8%). Metastases to the paranasal sinuses (PNS) are relatively common and may be a part of synchronous multiorgan involvement or present in follow-up after radical nephrectomy (metachronous); but primary presentation as isolated paranasal mass before the diagnosis of RCC is extremely rare. Here, we report a case of 74-year-old female presented with epistaxis and nasal obstruction. On evaluation by magnetic resonance imaging (MRI), a heterogeneously enhancing mass was found involving left PNS. Biopsy from mass revealed clear cell RCC. Later on, contrast-enhanced computed tomography (CECT) of chest, abdomen, and pelvis showed enhancing mass from the upper pole of the left kidney with no evidence of metastasis elsewhere. The patient was started on pazopanib 800 mg once a day. At 6 months follow-up scan, there was a partial response at both primary as well as metastatic site.

Keywords: Epistaxis; metastatic renal cell carcinoma; paranasal sinus; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
MRI head and neck showing T2 hyperintense lesion involving left frontal and ethmoid sinus with anterior cranial fossa extension
Figure 2
Figure 2
Rinoscopy showing proliferative mass
Figure 3
Figure 3
Diffuse spread of tumor cells in sheets, glands, and trabeculae having vacuolated clear cytoplasm and rounded nuclei and prominent nucleoli consistent with clear cell RCC (H & E ×40)
Figure 4
Figure 4
Tumor cells positive of RCCag (×40)
Figure 5
Figure 5
Coronal section CECT of the abdomen and pelvis showing heterogeneous enhancing mass at the mid and lower pole of the left kidney
See this image and copyright information in PMC

References

    1. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: A population-based study. Lancet Oncol. 2013;14:141–8. - PMC - PubMed
    1. Haddad H, Rini BI. Current treatment considerations in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2012;13:212–29. - PubMed
    1. Sountoulides P, Metaxa L, Cindolo L. Atypical presentations and rare metastatic sites of renal cell carcinoma: A review of case reports. J Med Case Rep. 2011;5:429. - PMC - PubMed
    1. Evgeniou E, Menon KR, Jones GL, Whittet H, Williams W. Renal cell carcinoma metastasis to the paranasal sinuses and orbit. BMJ Case Rep. 2012;2012:2–5. - PMC - PubMed
    1. Petruzzelli GJ, Shook T, Campbell WJ, Gupta S. Paranasal sinus metastases of renal cell carcinoma: A case report and comprehensive literature review. Ann Clin Case Rep. 2019;4:1642.

Publication types